摘要
目的探讨来氟米特(LEF)联合糖皮质激素治疗临床表现为肾病综合征的过敏性紫癜性肾炎(HSPN)的疗效和安全性。方法选取57例临床表现为肾病综合征的HSPN患者,随机分配为三组,每组19例,A组用来氟米特联合激素治疗,B组用环磷酰胺(CTX)联合激素治疗,C组用雷公藤多甙联合激素治疗,观察治疗后3组疗效及不良反应,并于治疗6个月时检查尿红细胞、尿蛋白及血白蛋白等指标,同时记录不良反应。结果①3组接受治疗后,尿蛋白和尿红细胞计数均明显减少(P<0.05),血白蛋白明显上升(P<0.05),且A、B组优于C组(P<0.05);②A组总有效率78.9%,B组总有效率73.7%,C组总有效率36.8%,A、B两组无统计学差异,C组与A/B组之间有统计学差异。结论 LEF是治疗临床表现为肾病综合征的HSPN的一种安全有效的药物。
Objective To evaluate the efficacy and safety of leflunomide and glucocorticoid being coapplied to treat nephropathy syndrome caused by henoch-sehonlein purpura nephritis （HSPN）. Methods 57 nephropathy syndrome patients caused by HSPN were randomly divided into three groups. Group A received leflunomide and prednisolone, group B received cyclophosphamide and prednisolone, and group C received gluco- sidal tripterygii TOTA and prednisolone. All patients were treated for more than 6 months. A series of experimental data was observed before and after the treatment for 6 months. Results （1）Mter treatment, proteinuria and urinary RBC count were deceased significantly （P 〈 0. 05）, and serum albumin was increased significantly （ P 〈 0.05） in three groups. Group A/B was more effective than group C （ P 〈 0.05 ）. （2）The total efficiency rates in group A,B and C were 78. 9% ,73.7% and 36. 8% respectively. There was no significant differences between group A and B. There was significant differences between group C and A/B. Conclusion Leflunomide is safe and effective for the treatment of nephropathy syndrome caused by HSPN.
出处
《中国现代药物应用》
2011年第23期1-3,共3页
Chinese Journal of Modern Drug Application
关键词
来氟米特
过敏性紫癜性肾炎
环磷酰胺
雷公藤多甙
Leflunomide
Henoch-schonlein purpura nephritis
Cyclophosphamide
Glucosidal tripterygii TOTA
